{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:22:47Z","timestamp":1767838967889,"version":"3.49.0"},"reference-count":35,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To analyse the association between refill adherence to lipid-lowering medications, and the risk of cardiovascular disease (CVD) and mortality in patients with type 2 diabetes mellitus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>National population-based cohort of Swedish patients with type 2 diabetes mellitus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>86\u2009568 patients aged \u226518 years, registered with type 2 diabetes mellitus in the Swedish National Diabetes Register, who filled at least one prescription for lipid-lowering medication use during 2007\u20132010, 87% for primary prevention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Exposure and outcome measures<\/jats:title><jats:p>Refill adherence of implementation was assessed using the medication possession ratio (MPR), representing the proportion of days with medications on hand during an 18-month exposure period. MPR was categorised by five levels (\u226420%, 21%\u201340%, 41%\u201360%, 61%\u201380% and &gt;80%). Patients without medications on hand for \u2265180 days were defined as non-persistent. Risk of CVD (myocardial infarction, ischaemic heart disease, stroke and unstable angina) and mortality by level of MPR and persistence was analysed after the exposure period using Cox proportional hazards regression and Kaplan-Meier, adjusted for demographics, socioeconomic status, concurrent medications and clinical characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The hazard ratios for CVD ranged 1.33\u20132.36 in primary prevention patients and 1.19\u20131.58 in secondary prevention patients, for those with MPR \u226480% (p&lt;0.0001). The mortality risk was similar regardless of MPR level. The CVD risk was 74% higher in primary prevention patients and 33% higher in secondary prevention patients, for those who were non-persistent (p&lt;0.0001). The mortality risk was 6% higher in primary prevention patients and 18% higher in secondary prevention patients, for non-persistent patients (p&lt;0.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Higher refill adherence to lipid-lowering medications was associated with lower risk of CVD in primary and secondary prevention patients with type 2 diabetes mellitus.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2017-020309","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T13:25:51Z","timestamp":1522416351000},"page":"e020309","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-9587","authenticated-orcid":false,"given":"Sofia Axia","family":"Karlsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Hero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Marie","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Franz\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervete","family":"Miftaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soffia","family":"Gudbj\u00f6rnsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Eeg-Olofsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Andersson Sundell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"2020050713361320000_8.3.e020309.1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in Type 1 and Type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2020050713361320000_8.3.e020309.2","unstructured":"World Health Organization. Global report on diabetes. Geneva, 2016. http:\/\/www.who.int\/diabetes\/global-report\/en\/"},{"key":"2020050713361320000_8.3.e020309.3","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S012"},{"key":"2020050713361320000_8.3.e020309.4","unstructured":"International Diabetes Federation. Cardiovascular risk protection. Global guideline for Type 2 Diabetes. Brussels, 2012. http:\/\/www.idf.org"},{"key":"2020050713361320000_8.3.e020309.5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2125.2010.03895.x","article-title":"Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study","volume":"71","author":"Ruokoniemi","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2020050713361320000_8.3.e020309.6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/pds.3936","article-title":"Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes","volume":"25","author":"Korhonen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020050713361320000_8.3.e020309.7","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12339"},{"key":"2020050713361320000_8.3.e020309.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04167.x"},{"key":"2020050713361320000_8.3.e020309.9","unstructured":"World Health Organization. Adherence of long-term therapies: evidence for action. Geneva 2003 http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_report\/en\/."},{"key":"2020050713361320000_8.3.e020309.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"2020050713361320000_8.3.e020309.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"2020050713361320000_8.3.e020309.12","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.diabres.2008.12.015","article-title":"Persistence with statin therapy in diabetic and non-diabetic persons: a nation-wide register study in 1995-2005 in Finland","volume":"84","author":"Helin-Salmivaara","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"2020050713361320000_8.3.e020309.13","doi-asserted-by":"crossref","unstructured":"Ruokoniemi P , Sund R , Arffman M , et al . Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. BMJ Open 2014;4:e005402.doi:10.1136\/bmjopen-2014-005402","DOI":"10.1136\/bmjopen-2014-005402"},{"key":"2020050713361320000_8.3.e020309.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht295"},{"key":"2020050713361320000_8.3.e020309.15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-6-48"},{"key":"2020050713361320000_8.3.e020309.16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"2020050713361320000_8.3.e020309.17","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0168-8227(14)70732-6","article-title":"Diabetes care-improvement through measurement","volume":"106\u00a0(Suppl 2)","author":"Eliasson","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2020050713361320000_8.3.e020309.18","unstructured":"National Board of Health and Welfare. The National Patient Register. http:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/patientregistret\/inenglish (accessed 1 Apr 2015)."},{"key":"2020050713361320000_8.3.e020309.19","unstructured":"Statistics Sweden. Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym). http:\/\/www.scb.se\/lisa-en (accessed 1 Apr 2015)."},{"key":"2020050713361320000_8.3.e020309.20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/dom.12704","article-title":"Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register","volume":"18","author":"Ekstr\u00f6m","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2020050713361320000_8.3.e020309.21","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0068-9"},{"key":"2020050713361320000_8.3.e020309.22","unstructured":"The Dental and Pharmaceutical Benefits Agency. Ordinance (2002:687) on Pharmaceutical Benefits, etc. SFS 2002;2002."},{"key":"2020050713361320000_8.3.e020309.23","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/pds.4281","article-title":"Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study","volume":"26","author":"Karlsson","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020050713361320000_8.3.e020309.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001076"},{"key":"2020050713361320000_8.3.e020309.25","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.329"},{"key":"2020050713361320000_8.3.e020309.26","unstructured":"Core Team R. R: a language and environment for statistical computing. Vienna, 2013. http:\/\/www.r-project.org\/"},{"key":"2020050713361320000_8.3.e020309.27"},{"key":"2020050713361320000_8.3.e020309.28","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2020050713361320000_8.3.e020309.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31075-9"},{"key":"2020050713361320000_8.3.e020309.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2015.08.032"},{"key":"2020050713361320000_8.3.e020309.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009116"},{"key":"2020050713361320000_8.3.e020309.32","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1925"},{"key":"2020050713361320000_8.3.e020309.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01630.x"},{"key":"2020050713361320000_8.3.e020309.34","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1230"},{"key":"2020050713361320000_8.3.e020309.35","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2204"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-020309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T03:22:04Z","timestamp":1601090524000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-020309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,8]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/bmjopen-2017-020309"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-020309","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}